SCHEMBL2302840

SCHEMBL2302840

Cc1cccc(OS(=O)(=O)c2ccc(N3CCNC3=O)cc2)c1C

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.45
CMA1 P23946 2/20 0.42
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
ESR1 P03372 1/20 0.37
GAA P10253 1/20 0.37
ESR2 Q92731 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP1A1 P04798 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12353646 0.90 LMNA (0.41) HTR6CMA1MEN1KMT2ASMN1; SMN2
SCHEMBL2235517 0.84 MAPT (0.42) HTR6MEN1KMT2AESR1GAA
SCHEMBL2303708 0.82 CYP1A1 (0.38) CMA1GAASMN1; SMN2ALDH1A1CYP1A1
SCHEMBL2303210 0.82 ALDH1A1 (0.48) CMA1GAAALDH1A1CYP1A1
SCHEMBL2299623 0.81 LMNA (0.39) HTR6MEN1KMT2AGAASMN1; SMN2
SCHEMBL2301814 0.81 LMNA (0.39) HTR6MEN1KMT2AGAASMN1; SMN2
SCHEMBL2305210 0.81 DHODH (0.47) HTR6CMA1MEN1KMT2ASMN1; SMN2
SCHEMBL2304331 0.80 L3MBTL1 (0.39) CMA1MEN1KMT2AALDH1A1CYP3A4
SCHEMBL2304867 0.80 CYP1A1 (0.44) GAASMN1; SMN2ALDH1A1CYP1A1
SCHEMBL2298515 0.80 POLB (0.40) HTR6CMA1MEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 HTR6 4117/4885CMA1 4171/4885MEN1 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.